Talon claims Marqibo is a novel, targeted Optisome encapsulated formulation product candidate of the FDA-approved anticancer drug Vincristine.
The company is developing Marqibo as a treatment for Ph- ALL in adults.
Talon president and CEO Steven Deitcher said they believe Marqibo has the potential to be an effective treatment beyond their initial sought indication of adult Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia in second or greater relapse or that has progressed following two or more prior lines of anti-leukemia therapy.